---
title: Lab Members Presenting at the 82nd Annual Meeting of the Japan Cancer Association
last_modified_at: ""
tags: 
  - Conference
image: https://user-images.githubusercontent.com/81615397/274549061-3cd32f3e-6f8e-4a89-9d9a-60d172a18338.png
---

Lab members Dr. Yang Weiqin, Dr. Tu Yalin, with Prof. Alfred Cheng recently attended [the 82nd Annual Meeting of the Japan Cancer Association](https://www.c-linkage.co.jp/jca2023/en/contents/program.html), held at Pacifico Yokohama from September 21st to September 23rd. 

The conference brought together experts and researchers from the field of cancer, providing a platform for sharing valuable insights and advancements.

<p align="center" width="60%">
    <img src="https://user-images.githubusercontent.com/81615397/274549061-3cd32f3e-6f8e-4a89-9d9a-60d172a18338.png">
</p>

Dr. Yang Weiqin and Dr. Tu Yalin were selected to deliver oral presentations, showcasing their respective research. Dr. Yang Weiqin(Left) presented her study titled "Selective HDAC8 Inhibition Potentiates Tumor Remission and Durable Benefit by PD-L1 Blockade," which explored the potential of HDAC8 inhibition in enhancing the efficacy of PD-L1 blockade for tumor treatment. Dr. Tu Yalin(Right) shared his research on "Epigenetic Activation of Tumoral IFN-gamma Response and Pyroptosis Overcoming Immunotherapy Resistance in HCC," shedding light on the role of epigenetic modifications in overcoming immunotherapy resistance in hepatocellular carcinoma (HCC).

<p align="center" width="95%">
    <img width="49%" src="https://user-images.githubusercontent.com/81615397/274549078-921e4681-ce12-4e8f-80ae-0c384a8f0c6c.png">
    <img width="49%" src="https://user-images.githubusercontent.com/81615397/274553377-27557d12-ecfd-4a99-b0ad-97288e16373c.png">
</p>

In addition, Prof. Alfred Cheng was invited to present at a symposium focused on "Tumor Adaptation and Re-sensitization to Immune Checkpoint Therapy." Prof. Cheng shared valuable insights into strategies for overcoming tumor adaptation and re-sensitizing patients to immune checkpoint therapy.

<p align="center" width="60%">
    <img src="https://user-images.githubusercontent.com/81615397/274548997-4340841c-942f-4996-829d-4f4cdc978d1b.png">
</p>

The participation at the conference provided a valuable opportunity to share their research and engage with experts in the field. Their contributions at the conference represent the ongoing efforts of our lab to advance cancer research and improve patient outcomes.